Objectives

After participating in this educational activity, attendees should be able to:
1. Identify diagnostic tools for the identification of suspected breast implant-associated ALCL 
2. Discuss disease course and oncologic progression of breast implant-associated ALCL
3. Describe current first and second line treatment modalities and reported outcomes
4. Describe current FDA recommendations regarding breast implant-associated ALCL
 

Faculty

Mark W. Clemens II, MD, FACS
Associate Professor of Plastic Surgery
University of Texas In Houston
MD Anderson Cancer Center 

None of the members of the faculty and planning committee for this educational event have commercial relationships with any entity producing, marketing, re-selling or distributing health care goods and services consumed by or used on patients.